According to the FDA, at least five million cases of infection have been recorded in the past 15 years.
“Chikungunya virus infections can lead to serious and long-term health problems, especially for the elderly and individuals with medical history,” said Peter Marks, a senior official at the US agency, in the statement.
Two clinical trials conducted
The vaccine is administered in a single dose and contains the attenuated virus – a classic technique used for other vaccines.
Two clinical trials were conducted in North America on several thousand people. The main side effects are headaches, fatigue, muscle aches, or nausea. In rare cases, more serious reactions have been observed, the FDA noted. Two participants in the clinical trials who received the vaccine had to be hospitalized.
A request for authorization has also been submitted by Valneva to the European Medicines Agency (EMA).
#Les #EtatsUnis #approuvent #premier #vaccin #contre #chikungunya
publish_date]
